Hot Features
プレミアム
Keros Therapeutics Inc (KROS)
NASDAQ
ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candida... Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. 詳細を表示
LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros will host an update call and webcast today, December 12, 2024, at 8:00 a.m. ET LEXINGTON, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...
Elritercept demonstrated a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden, with a median duration of response of 134.1...
Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.58 | -12.1632024634 | 12.99 | 13.08 | 9.775 | 5229616 | 10.60961443 | CS |
| 4 | -5.71 | -33.3528037383 | 17.12 | 17.25 | 9.775 | 2060766 | 12.27482733 | CS |
| 12 | -48.66 | -81.0054935908 | 60.07 | 72.37 | 9.775 | 1390804 | 23.34484812 | CS |
| 26 | -37.36 | -76.604469961 | 48.77 | 72.37 | 9.775 | 797405 | 30.36257428 | CS |
| 52 | -41.66 | -78.5000942152 | 53.07 | 73 | 9.775 | 578853 | 38.34237184 | CS |
| 156 | -35.1 | -75.4676413674 | 46.51 | 73 | 9.775 | 343317 | 39.69658986 | CS |
| 260 | -8.69 | -43.2338308458 | 20.1 | 88.8 | 9.775 | 267172 | 42.04804472 | CS |
TheFinalCD
6日前
retireat40
1月前
retireat40
1月前
Dennis14
1月前
Monksdream
4月前
Monksdream
11月前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
